Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA1158
  • Published: 
The second committee meeting for this topic has now been scheduled for Wednesday 13 August 2025. This is to ensure Johnson & Johnson Innovative Medicine and all other stakeholders have sufficient time to review the Draft Guidance and provide the full evidence needed to inform the committee’s recommendations

This page was last updated: